Uncategorized
Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in the January 2018 issue of the Journal of Glaucoma showed that a single iStent® Trabecular Micro-Bypass Stent implanted during cataract surgery in patients with severe open-angle glaucoma achieved mean post